Strategic report Governance & remuneration Financial statements Investor information 27 Trade and other payables 2015 2014 m m Trade payables 3,120 2,790 Wages and salaries 1,069 957 Social security 118 91 Other payables 368 301 Deferred income 73 62 Customer return and rebate accruals 2,056 1,774 Contingent consideration 306 105 Other accruals 2,081 1,878 9,191 7,958 Customer return and rebate accruals are provided for by the Group at the point of sale in respect of the estimated rebates, discounts or allowances payable to customers, including 1,464 million 2014 1,308 million in respect of US Pharmaceuticals and Vaccines.
Accruals are made at the time of sale but the actual amounts paid are based on claims made some time after the initial recognition of the sale.
As the amounts are estimated they may not fully reect the final outcome and are subject to change dependent upon, amongst other things, the types of buying group and product sales mix.
The level of accrual is reviewed and adjusted quarterly in the light of historical experience of actual rebates, discounts or allowances given and returns made and any changes in arrangements.
Future events could cause the assumptions on which the accruals are based to change, which could affect the future results of the Group.
Trade and other payables include 17 million 2014 9 million due to associates and joint ventures.
28 Pensions and other post-employment benets 2015 2014 2013 Pension and other post-employment costs m m m UK pension schemes 177 125 139 US pension schemes 96 85 95 Other overseas pension schemes 135 123 111 Unfunded post-retirement healthcare schemes 59 70 175 467 403 170 Analysed as: Funded dened benefit hybrid pension schemes 345 267 283 Unfunded dened benefit pension schemes 36 34 30 Unfunded post-retirement healthcare schemes 59 70 175 Dened benefit schemes 440 371 138 Dened contribution pension schemes 27 32 32 467 403 170 The net reduction in the post-retirement healthcare schemes cost in 2013 arises from the restructuring of US post-retirement medical obligations.
For further details see page 171.
The costs of the dened benefit pension and post-retirement healthcare schemes are charged in the income statement as follows: 2015 2014 2013 m m m Cost of sales 143 117 104 Selling, general and administration 225 194 27 Research and development 72 60 7 440 371 138 GSK entities operate pension arrangements which cover the Groups material obligations to provide pensions to retired employees.
These arrangements have been developed in accordance with local practices in the countries concerned.
Pension benets can be provided by state schemes: by dened contribution schemes, whereby retirement benets are determined by the value of funds arising from contributions paid in respect of each employee: or by dened benefit schemes, whereby retirement benets are based on employee pensionable remuneration and length of service.
Some hybrid dened benefit schemes also include dened contribution sections.
